Copertina

Assessing the applicability of the DOAC, HAS‐BLED and ORBIT risk scores in Chinese patients on non‐vitamin K antagonist oral anticoagulants

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Miao Fan, Xuan Yin, Yiyi Jin, Xiaomeng Zheng, Suyan Zhu
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	British Journal of Clinical Pharmacology
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Relevance of selected pharmacogenetic polymorphisms to bleeding and thromboembolic risks in Chinese patients taking direct‐acting oral anticoagulants
di: Dongxu Wang, et al.
Pubblicazione: (2025)

Association between oral anticoagulant therapy and in‐hospital complications and mortality
di: Juliana Lagrave, et al.
Pubblicazione: (2025)

Dicloxacillin is an inducer of intestinal P‐glycoprotein but neither dicloxacillin nor flucloxacillin increases the risk of stroke/systemic embolism in direct oral anticoagulant users
di: Ditte B. Iversen, et al.
Pubblicazione: (2024)

Effect of enzalutamide on anticoagulant therapy with edoxaban in patients with prostate cancer
di: Catharina J. P. Op 't Hoog, et al.
Pubblicazione: (2025)

Prescriptions of CYP3A4‐ and P‐gp inducers for patients on direct oral anticoagulants: Bridging the gap between epidemiology and patient management for optimal thromboembolic event prevention
di: Stephanie C. M. Wuyts, et al.
Pubblicazione: (2025)

Appropriateness of direct oral anticoagulant prescribing in older subjects with atrial fibrillation discharged from acute medical wards
di: Antonio De Vincentis, et al.
Pubblicazione: (2024)

Pharmacological evaluation of non‐nucleotide purine derivatives as P2X7 antagonists for the treatment of neuroinflammation in traumatic brain injury
di: Inés Valencia, et al.
Pubblicazione: (2025)

Anticoagulation reversal (vitamin K, prothrombin complex concentrates, idarucizumab, andexanet‐α, protamine)
di: Elias Bekka, et al.
Pubblicazione: (2024)

Integrative immunomodulation in systemic autoimmune diseases: Mechanistic complementarity and therapeutic strategies of traditional Chinese and conventional medicine
di: Xiaomeng Zhang, et al.
Pubblicazione: (2026)

How could perampanel, a potent AMPAergic antagonist, inhibit seizures but largely spare normal neurotransmission?
di: Cho‐Ming Lee, et al.
Pubblicazione: (2026)

A vitamin D‐based strategy overcomes chemoresistance in prostate cancer
di: Kateryna Len‐Tayon, et al.
Pubblicazione: (2024)

Investigation of absorption, metabolism, and excretion of [ 14 C]pruxelutamide (GT0918), an androgen receptor antagonist in humans
di: Yuan‐dong Zheng, et al.
Pubblicazione: (2025)

Intranasal vitamin B12 administration in elderly patients: A randomized controlled comparison of two dosage regimens
di: Monique P. H. Tillemans, et al.
Pubblicazione: (2024)

Direct neuronal protection by the protease‐activated receptor PAR4 antagonist ML354 after experimental stroke in mice
di: Michael Fleischer, et al.
Pubblicazione: (2024)

Sodium‐glucose cotransporter‐2 inhibitors and the risk of lung cancer among patients with type 2 diabetes
di: Samantha B. Shapiro, et al.
Pubblicazione: (2024)

The fast‐dissociating D 2 antagonist antipsychotic JNJ‐37822681 is a neuronal Kv7 channel opener: Potential repurposing for epilepsy treatment
di: Lidia Carotenuto, et al.
Pubblicazione: (2025)

ESG‐1‐60 and ESG‐1‐61: Novel dopamine D3 receptor‐preferring partial agonists/antagonists that inhibit cocaine taking and seeking in rodents
di: Omar Soler‐Cedeño, et al.
Pubblicazione: (2025)

Efficiency of computerized clinical decision support systems involving anticoagulants: A flashmob study in Dutch hospital pharmacies
di: Jetske Graafsma, et al.
Pubblicazione: (2024)

Discrepancies between forest plots and reported results in mineralocorticoid receptor antagonist meta‐analysis of glycaemic outcomes
di: Lekha Saha
Pubblicazione: (2026)

A comprehensive review of anti‐colorectal cancer alkaloids from traditional Chinese medicine: Sources, chemical structures, mechanisms and therapeutic applications
di: Kaiping Cong, et al.
Pubblicazione: (2026)

Pharmacodynamics of the orexin type 1 (OX1) receptor in colon cancer cell models: A two‐sided nature of antagonistic ligands resulting from partial dissociation of Gq
di: Valérie Gratio, et al.
Pubblicazione: (2024)

Maternal exposure to folate antagonists and susceptibility to congenital heart disease in offspring: A systematic review and meta‐analysis
di: Prajjwol Luitel, et al.
Pubblicazione: (2024)

The interplay between molecular architecture, pharmacology, and suspected adverse drug reactions associated with nonsteroidal androgen antagonists in the United Kingdom
di: Simrit Dhillon, et al.
Pubblicazione: (2026)

Development and validation of a clinical risk score nomogram for predicting clozapine plasma concentrations below 350 ng/mL: A retrospective cohort study
di: Jing Ding, et al.
Pubblicazione: (2025)

Exposure–response relationship of fedratinib in patients with intermediate‐2 or high‐risk myelofibrosis
di: Yizhe Chen, et al.
Pubblicazione: (2025)

Safe and supportive prescribing in transgender and non‐binary patients with cancer
di: Mariachiara D'Elia, et al.
Pubblicazione: (2024)

Inter‐regional pharmacokinetics and exposure–response analyses of belimumab in patients with system lupus erythematosus
di: Junyi Wu, et al.
Pubblicazione: (2024)

Safety and pharmacokinetics of a novel potent GABA analogue crisugabalin in Chinese subjects with various degrees of renal impairment
di: Shibeilei Lin, et al.
Pubblicazione: (2025)

Model‐based precision dosing and remedial dosing recommendations for delayed or missed doses of isoniazid in Chinese patients with tuberculosis
di: Jin‐Meng Li, et al.
Pubblicazione: (2024)

Development of a predictive model for neutropenia risk in Japanese breast cancer patients treated with doxorubicin and cyclophosphamide
di: Takehiro Miyagi, et al.
Pubblicazione: (2025)

The first in‐human study to evaluate the antiplatelet properties of the clopidogrel conjugate DT‐678 in acute coronary syndrome patients and healthy volunteers
di: Zhihao Liu, et al.
Pubblicazione: (2024)

An orally available Cav2.2 calcium channel inhibitor for the treatment of neuropathic pain
di: Janine Kutzsche, et al.
Pubblicazione: (2024)

Exploring the antidepressant potential of Yueju Pill: Insights from traditional Chinese medicine
di: Xinyan Wu, et al.
Pubblicazione: (2026)

STRATIfy‐PK SCORE: A predictive tool for identifying pharmacokinetic failure risk in anti‐TNF–treated patient
di: Carles Iniesta‐Navalón, et al.
Pubblicazione: (2025)

Methodological considerations for a deep learning‐based prescription framework for traditional Chinese medicine
di: Mingze Ma, et al.
Pubblicazione: (2026)

Niclosamide prodrug enhances oral bioavailability and efficacy against hepatocellular carcinoma by targeting vasorin‐TGFβ signalling
di: Mingdian Tan, et al.
Pubblicazione: (2025)

A deep neural network model for optimizing traditional Chinese medicine prescriptions with data augmentation
di: Xiaohan Mao, et al.
Pubblicazione: (2025)

Deprescribing drugs with anticholinergic effects in older patients with increased risk of dementia in the multicomponent intervention study AgeWell.de
di: Laura K. Lepenies, et al.
Pubblicazione: (2025)

External validation of the BAN‐ADHF diuretic‐resistance score in the DAPA‐RESIST clinical trial
di: Dominic M. Alfonso, et al.
Pubblicazione: (2026)

Pharmacodynamics, pharmacokinetics and CYP3A4 interaction potential of the selective P2X3 receptor antagonist filapixant: A randomized multiple ascending‐dose study in healthy young men
di: Christian Friedrich, et al.
Pubblicazione: (2024)